|
1
|
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
|
N Engl J Med
|
2006
|
6.90
|
|
2
|
High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
|
Lancet Oncol
|
2010
|
3.88
|
|
3
|
Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia.
|
N Engl J Med
|
2015
|
3.00
|
|
4
|
Immune activation in patients with irritable bowel syndrome.
|
Gastroenterology
|
2007
|
2.82
|
|
5
|
Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria.
|
Br J Haematol
|
2013
|
1.68
|
|
6
|
Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas.
|
Haematologica
|
2012
|
1.30
|
|
7
|
Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity.
|
Eur J Pharmacol
|
2005
|
1.16
|
|
8
|
Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease.
|
Blood
|
2009
|
1.08
|
|
9
|
Telomere shortening in leukocyte subpopulations from baboons.
|
J Leukoc Biol
|
2003
|
0.98
|
|
10
|
Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria.
|
N Engl J Med
|
2015
|
0.97
|
|
11
|
Expanded CD8+ T cells of murine and human CLL are driven into a senescent KLRG1+ effector memory phenotype.
|
Cancer Immunol Immunother
|
2013
|
0.88
|
|
12
|
Telomeres and prognosis in patients with chronic lymphocytic leukaemia.
|
Int J Hematol
|
2011
|
0.88
|
|
13
|
Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial.
|
Neurology
|
2012
|
0.83
|
|
14
|
Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria.
|
Br J Haematol
|
2008
|
0.83
|
|
15
|
Prognostic impact of intraocular involvement in primary CNS lymphoma: experience from the G-PCNSL-SG1 trial.
|
Ann Hematol
|
2014
|
0.78
|
|
16
|
Hand-foot syndrome: common presentation in an uncommon situation.
|
Eur J Haematol
|
2013
|
0.76
|
|
17
|
CLLU1 expression distinguishes chronic lymphocytic leukemia from other mature B-cell neoplasms.
|
Leuk Res
|
2012
|
0.75
|
|
18
|
Acral ischemia as a presenting manifestation of essential thrombocythemia.
|
Int J Hematol
|
2011
|
0.75
|
|
19
|
Nodular lesions of the scalp and a mediastinal mass in T cell acute lymphoblastic leukemia.
|
Int J Hematol
|
2010
|
0.75
|
|
20
|
Porphyria cutanea tarda.
|
Br J Haematol
|
2009
|
0.75
|
|
21
|
Amyloid tumour.
|
Br J Haematol
|
2009
|
0.75
|